John C. Byrd - Concepedia

Author

John C. Byrd

The Ohio State University ORCID

Also Known As

Alice S. Mims, Byrd, John, Byrd, John C, Cutler, Corey, J Byrd, J C Byrd, J. Byrd, J. C. Byrd, J.C. Byrd, JOHN C BYRD

1.3K

Publications

63.6K

Citations

116

H-Index

188

Concepts

All Affiliations

The Ohio State University Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center Cornell University Stanford University

About

John C. Byrd is an author at The Ohio State University specializing in medicine, immunology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	56	153	24.9K
2	Health Sciences	21	38	3K
3	Engineering	4	4	1.2K
4	Business	1	1	17
5	Management	1	1	17

John C. Byrd

462

Publications

58.4K

Citations

111

H-Index

Page 1

	Year	Citations
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Ash A. Alizadeh, Michael B. Eisen, R. Eric Davis, Nature Hematological MalignancyLymphoid NeoplasiaImmunologyDistinct TypesPathology	2000	9.9K
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg, The Lancet Oncology Hematological MalignancyHigher-risk Myelodysplastic SyndromesHematologyPharmacotherapyMedicine	2009	2.6K
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Blood	2018	1.6K
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu, New England Journal of Medicine	2014	1.2K
Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia Andreas Rosenwald, Ash A. Alizadeh, George F. Widhopf, The Journal of Experimental Medicine Rearranged ImmunoglobulinEngineeringMixed-phenotype Acute LeukemiaGeneticsImmunology	2001	1.1K
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia John C. Byrd, Bonnie K. Harrington, Susan O’Brien, New England Journal of Medicine	2015	878
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody Don M. Benson, Courtney E. Bakan, Anjali Mishra, Blood	2010	797
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 Sarah E. M. Herman, Amber Gordon, Erin Hertlein, Blood	2011	789
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan, Blood	2013	783
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1 Ramiro Garzon, Shujun Liu, Muller Fabbri, Blood	2009	768

Page 1